The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 16, 2023

Filed:

Apr. 02, 2021
Applicant:

Petra Pharma Corporation, New York, NY (US);

Inventors:

Erin Danielle Anderson, Boulder, CO (US);

Sean Douglas Aronow, Boulder, CO (US);

Nicholas A. Boyles, Hillsboro, OR (US);

Markus K. Dahlgren, Shelton, CT (US);

Shulu Feng, Ridgewood, NJ (US);

Aleksey I. Gerasyuto, Flemington, NJ (US);

Eugene R. Hickey, Danbury, CT (US);

Thomas Combs Irvin, Erie, CO (US);

Edward A. Kesicki, New York, NY (US);

Anke Klippel-Giese, Princeton, NJ (US);

Jennifer Lynn Knight, Jersey City, NJ (US);

Gabrielle R. Kolakowski, Longmont, CO (US);

Manoj Kumar, Longmont, CO (US);

Katelyn Frances Long, Lafayette, CO (US);

Christopher Glenn Mayne, Boulder, CO (US);

David L. McElligott, Bothell, WA (US);

Johnathan Alexander McLean, Indianapolis, IN (US);

Loredana Puca, New York, NY (US);

Kannan Karukurichi Ravi, Fords, NJ (US);

Daniel Lee Severance, San Diego, CA (US);

Michael Brian Welch, Westminister, CO (US);

Tien Widjaja, Lafayette, CO (US);

Assignee:

Petra Pharma Corporation, New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 405/04 (2006.01); C07D 405/14 (2006.01); C07D 491/056 (2006.01);
U.S. Cl.
CPC ...
C07D 405/04 (2013.01); C07D 405/14 (2013.01); C07D 491/056 (2013.01);
Abstract

The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, R, R, W, X, Y, s, and Ring A are as described herein.


Find Patent Forward Citations

Loading…